{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.7","upperLimit":"80.2","value":"60.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"ORR per IMWG criteria: percentage of participants with best overall response (BOR) of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). sCR: complete response plus normal free light chain (FLC) ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR: negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in bone marrow aspirates. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or \\>=90% reduction in serum M-protein plus urine M-protein level \\<100 mg/24 hr. PR: \\>=50% reduction of serum M-protein and reduction in 24 hrs urinary M-protein by \\>=90% or to \\<200 mg/24 hr. If serum and urine M-protein were unmeasurable, \\>=50% decrease in difference between involved and uninvolved FLC levels required in place of the M-protein criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 44 mcg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 76 mcg as a SC injection Q1W on Day 1, 8, 15 and 22 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG000","title":"Part 2A: PF-06863135 SC"}],"paramType":"NUMBER","populationDescription":"Modified intent to treat (mITT) analysis set included all participants who have received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"From the first dose of study treatment until the first documented sCR or CR or PR or VGPR or new anti-cancer therapies or death, whichever occurred first (maximum up to 34.3 months)","title":"Part 2: Objective Response Rate (ORR) as Per International Myeloma Working Group (IMWG) Criteria","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}